As outside health experts and advocates push HICPAC to consider improving mask standards, ventilation, and related guidance in healthcare settings, one group has led the advocacy effort: National Nurses United (NNU). NNU’s organizing efforts around the HICPAC guidance have included a number of letters and petitions to the CDC, organizing speakers at the public comment sections of HICPAC meetings, and pushing for greater transparency around how the committee makes decisions.
As winter approaches, pretty much every public health expert I follow is anticipating a COVID-19 surge. The size and severity of that surge may depend in part on SARS-CoV-2 variants. As a result, experts are closely watching a few current variants that might lead to faster COVID-19 spread this winter. Here’s a review of what’s circulating right now, what to watch for in the coming weeks, and how our public health system is tracking the variants.
Our mid-fall COVID-19 lull continues in the U.S., with major metrics showing plateaus in disease spread nationally. A disruption in wastewater surveillance may make it harder to follow these trends in the coming weeks.
Two weeks ago I wrote an article explaining that the CDC has a new wastewater contract, essentially transferring responsibility for COVID-19 testing at hundreds of wastewater treatment plants across the country from Biobot Analytics to a company called Verily, which is affiliated with Google. In the time since that post, I have seen some other articles and social media posts alleging that, thanks to the contract change, Biobot will no longer be posting any COVID-19 data on their dashboard. This is inaccurate!
If you’re a science journalist interested in using datasets to tell stories, you might be interested in a workshop that I will be running with The Open Notebook on October 31 that will cover reporting and producing data stories about science topics.
Starting in 2024, the antiviral drug Paxlovid will be a private—and expensive—treatment for COVID-19. The Department of Health and Human Services (HHS) announced about a week ago that it’s reached a deal with Pfizer, the pharmaceutical company that produces Paxlovid, to “transition” this drug into the commercial market within the next few months. The transition will lead to Paxlovid becoming even less accessible than it is now and will exacerbate health inequities that we’ve seen with this drug.
Major metrics suggest the U.S. is still in a lull of COVID-19 spread, as we’ve seen decreases in wastewater levels and test positivity for several weeks. Transmission is still high, though, and it seems likely that cold weather will drive up COVID-19 as well as other respiratory viruses in the coming weeks.
Despite impacting millions of people prior to the pandemic, ME/CFS is not well studied; research into the condition is underfunded, and doctors typically don’t learn about it during their training. A new paper from the Rochester Mayo Clinic and ME Action, a ME/CFS advocacy group, may help change this, by offering guidelines for doctors who have patients with this condition.
